SynthesisClinical obesity2025
Effect of glucagon-like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta-analysis.
Synthesis in Clinical obesity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of glucagon-like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta-analysis.Clinical obesity · 2025Pooled it
- Article
- Comparison of renal outcomes between sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist in Japanese patients with type 2 diabetes and obesity.Clinical and experimental nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of glucagon-like peptide 1 receptor agonists (GLP-1RAs) on systolic blood pressure (SBP) in patients with obesity with or without diabetes remains unclear. The aim was to compare the effect of different drug-dose combinations of GLP-1RAs on SBP. The secondary aim was to assess whether changes in SBP with GLP-1RAs are associated with weight change. MEDLINE and Cochrane were searched until January 2022 for randomized control trials (RCTs) on patients with obesity, evaluating the impact of semaglutide, liraglutide, efpeglenatide, or exenatide on SBP. Separate analyses were done for trials with and without diabetes. Multivariate meta-regression assessed if SBP changes with GLP-1RA varied based on weight change or follow-up duration. Thirty-five RCTs were included. Follow-up duration ranged from 12 to 68 weeks for T2DM and 12-56 weeks for non-T2DM patients. GLP-1RAs significantly lowered SBP for all patients (MD = -3.14 [-3.60; -2.68]). Subgroup analysis showed a significantly greater difference in SBP reduction for patients without diabetes (-3.80 [-4.24; -3.37]) when compared with patients with diabetes (-2.13 [-3.27; -1.00]). Among patients with diabetes, liraglutide < 2 mg OD showed the greatest reduction in SBP (-3.78 [-6.27; -1.28]), while efpeglenatide ≤ 6 mg QW showed the greatest reduction in SBP (-6.00 [-9.89; -2.11]) in patients without diabetes. GLP-1RAs result in mild reductions in SBP in patients with obesity. The change in SBP varies only slightly by the drug-dose combination and appears to be related to the amount of weight loss.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.